REGIMEN COMPLEXITY, CLINICAL RESPONSE AND DIRECT MEDICATION COSTS IN TYPE 2 DIABETES: A RETROSPECTIVE REAL-WORLD COHORT STUDY FROM PRIMARY CARE IN KAZAKHSTAN
Farmaciâ Kazahstana · 30.10.2026 · 46
DOI: 10.53511/pharmkaz.2026.5.4 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Farmaciâ Kazahstana, online erschienen am 30.10.2026. Verfasst von Indira Kaibagarova und 5 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
The increasing prevalence of type 2 diabetes mellitus (T2DM) is accompanied by growing demand for long-term glucose-lowering therapy and a substantial economic burden on both patients and healthcare systems. In routine clinical practice, treatment decisions are influenced not only by clinical effectiveness but also by medication availability, prescribing patterns, and treatment costs. Therefore, pharmacoepidemiological and pharmacoeconomic evaluation of glucose-lowering therapy may provide valuable information for optimizing diabetes management in primary healthcare settings.
Objective
To perform a pharmacoepidemiological and pharmacoeconomic analysis of oral glucose-lowering therapy among patients with type 2 diabetes mellitus receiving primary healthcare in Aktobe, Kazakhstan.
Methods
A retrospective study of medical records of patients with T2DM receiving routine follow-up between April 2024 and April 2025 was conducted. After applying the inclusion and exclusion criteria, 232 patients were included in the analysis. Treatment patterns, clinical and demographic characteristics, achievement of the predefined HbA1c research threshold, clinical response to therapy, and direct medication costs were evaluated. Logistic and linear regression analyses were used to identify factors associated with treatment response and therapy costs. A pharmacoeconomic analysis of direct medication costs was performed, including calculation of the cost per responder (CER).
Results
Dual oral therapy was the most common treatment strategy (50.9%), followed by monotherapy (34.5%) and triple therapy (14.7%). Metformin was included in 84.5% of treatment regimens. The predefined HbA1c research threshold of
Zitieren
APA
Kaibagarova, I., Sartayeva, A., Smagulova, G., Mavlyudova, N., Zhamaliyeva, L., & Ovsiannikova, A. (2026). REGIMEN COMPLEXITY, CLINICAL RESPONSE AND DIRECT MEDICATION COSTS IN TYPE 2 DIABETES: A RETROSPECTIVE REAL-WORLD COHORT STUDY FROM PRIMARY CARE IN KAZAKHSTAN. Farmaciâ Kazahstana, 46. https://doi.org/10.53511/pharmkaz.2026.5.4
Vancouver
Kaibagarova I, Sartayeva A, Smagulova G, Mavlyudova N, Zhamaliyeva L, Ovsiannikova A. REGIMEN COMPLEXITY, CLINICAL RESPONSE AND DIRECT MEDICATION COSTS IN TYPE 2 DIABETES: A RETROSPECTIVE REAL-WORLD COHORT STUDY FROM PRIMARY CARE IN KAZAKHSTAN. Farmaciâ Kazahstana. 2026:46. doi:10.53511/pharmkaz.2026.5.4
BibTeX
@article{Kaibagarova2026,
author = {Kaibagarova, Indira and Sartayeva, Aigul and Smagulova, Gaziza and Mavlyudova, Nadiya and Zhamaliyeva, Lazzat and Ovsiannikova, Alla},
title = {REGIMEN COMPLEXITY, CLINICAL RESPONSE AND DIRECT MEDICATION COSTS IN TYPE 2 DIABETES: A RETROSPECTIVE REAL-WORLD COHORT STUDY FROM PRIMARY CARE IN KAZAKHSTAN},
journal = {Farmaciâ Kazahstana},
year = {2026},
pages = {46},
doi = {10.53511/pharmkaz.2026.5.4}
}
EUVIMED